Cargando…

Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice

BACKGROUND: Chronic gastritis has been demonstrated to be a key cause of gastric cancer (GC), and control of gastric inflammation is regarded as an effective treatment for the clinical prevention of gastric carcinogenesis. However, there remains an unmet need to identify the dominant regulators of g...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Wang-Yu, Lin, Ling-Yun, Wang, Lin, Yang, Li, Ye, Guo-Dong, Zeng, Qiang, Cheng, Jia, Xie, Yuan-Yuan, Chen, Mao-Li, Luo, Qi-Cong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617686/
https://www.ncbi.nlm.nih.gov/pubmed/31288844
http://dx.doi.org/10.1186/s12964-019-0387-6
_version_ 1783433747481231360
author Cai, Wang-Yu
Lin, Ling-Yun
Wang, Lin
Yang, Li
Ye, Guo-Dong
Zeng, Qiang
Cheng, Jia
Xie, Yuan-Yuan
Chen, Mao-Li
Luo, Qi-Cong
author_facet Cai, Wang-Yu
Lin, Ling-Yun
Wang, Lin
Yang, Li
Ye, Guo-Dong
Zeng, Qiang
Cheng, Jia
Xie, Yuan-Yuan
Chen, Mao-Li
Luo, Qi-Cong
author_sort Cai, Wang-Yu
collection PubMed
description BACKGROUND: Chronic gastritis has been demonstrated to be a key cause of gastric cancer (GC), and control of gastric inflammation is regarded as an effective treatment for the clinical prevention of gastric carcinogenesis. However, there remains an unmet need to identify the dominant regulators of gastric oncogenesis-associated inflammation in vivo. METHODS: The mouse model for the study of inflammation-associated GC was induced by Benzo[a]pyrene (BaP) intragastric administration in Bcl6b(−/−) and wildtype mice on a C57BL/6 background. 5-Aza-2′-deoxycytidine (5-Aza), the demethylation drug, was intraperitoneally injected to restore Bcl6b expression. Human GC tissue array was used to analyse patient survival based on BCL6B and CD3 protein expression. RESULTS: Bcl6b was gradually downregulated by its own promoter hypermethylation in parallel to an increasing inflammatory response during the progression of BaP-induced gastric carcinogenesis in mice. Moreover, knockout of Bcl6b dramatically worsened the severity of gastric cancer and aggravated the inflammatory response in the BaP-induced mice GC model. Re-activation of Bcl6b by 5-Aza impeded inflammatory amplification and BaP-induced GC development, prolonging survival time in wildtype mice, whereas no notable curative effect occurred in Bcl6b(−/−) mice with 5-Aza treatment. Finally, significant negative correlations were detected between the mRNA levels of BCL6B and inflammatory cytokines in human GC tissues; patients harbouring BCL6B-negetive and severe-inflammation GC tumours were found to exhibit the shortest survival time. CONCLUSIONS: Epigenetic inactivation of Bcl6b promotes gastric cancer through amplification of the gastric inflammatory response in vivo and offers a new approach for GC treatment and regenerative medicine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12964-019-0387-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6617686
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66176862019-07-22 Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice Cai, Wang-Yu Lin, Ling-Yun Wang, Lin Yang, Li Ye, Guo-Dong Zeng, Qiang Cheng, Jia Xie, Yuan-Yuan Chen, Mao-Li Luo, Qi-Cong Cell Commun Signal Research BACKGROUND: Chronic gastritis has been demonstrated to be a key cause of gastric cancer (GC), and control of gastric inflammation is regarded as an effective treatment for the clinical prevention of gastric carcinogenesis. However, there remains an unmet need to identify the dominant regulators of gastric oncogenesis-associated inflammation in vivo. METHODS: The mouse model for the study of inflammation-associated GC was induced by Benzo[a]pyrene (BaP) intragastric administration in Bcl6b(−/−) and wildtype mice on a C57BL/6 background. 5-Aza-2′-deoxycytidine (5-Aza), the demethylation drug, was intraperitoneally injected to restore Bcl6b expression. Human GC tissue array was used to analyse patient survival based on BCL6B and CD3 protein expression. RESULTS: Bcl6b was gradually downregulated by its own promoter hypermethylation in parallel to an increasing inflammatory response during the progression of BaP-induced gastric carcinogenesis in mice. Moreover, knockout of Bcl6b dramatically worsened the severity of gastric cancer and aggravated the inflammatory response in the BaP-induced mice GC model. Re-activation of Bcl6b by 5-Aza impeded inflammatory amplification and BaP-induced GC development, prolonging survival time in wildtype mice, whereas no notable curative effect occurred in Bcl6b(−/−) mice with 5-Aza treatment. Finally, significant negative correlations were detected between the mRNA levels of BCL6B and inflammatory cytokines in human GC tissues; patients harbouring BCL6B-negetive and severe-inflammation GC tumours were found to exhibit the shortest survival time. CONCLUSIONS: Epigenetic inactivation of Bcl6b promotes gastric cancer through amplification of the gastric inflammatory response in vivo and offers a new approach for GC treatment and regenerative medicine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12964-019-0387-6) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-09 /pmc/articles/PMC6617686/ /pubmed/31288844 http://dx.doi.org/10.1186/s12964-019-0387-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cai, Wang-Yu
Lin, Ling-Yun
Wang, Lin
Yang, Li
Ye, Guo-Dong
Zeng, Qiang
Cheng, Jia
Xie, Yuan-Yuan
Chen, Mao-Li
Luo, Qi-Cong
Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice
title Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice
title_full Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice
title_fullStr Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice
title_full_unstemmed Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice
title_short Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice
title_sort inhibition of bcl6b promotes gastric cancer by amplifying inflammation in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617686/
https://www.ncbi.nlm.nih.gov/pubmed/31288844
http://dx.doi.org/10.1186/s12964-019-0387-6
work_keys_str_mv AT caiwangyu inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice
AT linlingyun inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice
AT wanglin inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice
AT yangli inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice
AT yeguodong inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice
AT zengqiang inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice
AT chengjia inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice
AT xieyuanyuan inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice
AT chenmaoli inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice
AT luoqicong inhibitionofbcl6bpromotesgastriccancerbyamplifyinginflammationinmice